Top Page
InspireMD
(NASDAQ:NSPR)
InspireMD (NSPR) vs. SPDR S&P 500 ETF (SPY)
InspireMD Business Overview & Revenue Model
InspireMD Earnings Call Summary
InspireMD Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.07M | 7.01M | 6.21M | 5.17M | 4.50M | 2.48M |
| Gross Profit | 1.49M | 1.51M | 1.81M | 1.12M | 754.00K | 83.00K |
| EBITDA | -41.96M | -33.22M | -20.91M | -18.52M | -14.55M | -10.23M |
| Net Income | -41.38M | -32.01M | -19.92M | -18.49M | -14.92M | -10.54M |
Balance Sheet | ||||||
| Total Assets | 33.34M | 46.81M | 47.64M | 24.65M | 39.71M | 17.78M |
| Cash, Cash Equivalents and Short-Term Investments | 19.37M | 34.64M | 39.02M | 17.80M | 34.04M | 12.64M |
| Total Debt | 3.42M | 2.34M | 1.59M | 1.61M | 1.20M | 999.00K |
| Total Liabilities | 13.10M | 10.72M | 8.14M | 7.26M | 6.18M | 5.61M |
| Stockholders Equity | 20.24M | 36.09M | 39.50M | 17.39M | 33.53M | 12.16M |
Cash Flow | ||||||
| Free Cash Flow | -31.24M | -23.27M | -16.76M | -16.02M | -13.55M | -9.17M |
| Operating Cash Flow | -29.57M | -21.87M | -16.38M | -15.54M | -13.21M | -9.08M |
| Investing Cash Flow | 9.34M | 12.64M | -16.09M | 8.44M | -22.46M | -187.00K |
| Financing Cash Flow | 3.24M | 18.45M | 37.53M | -140.00K | 35.03M | 16.39M |
InspireMD Technical Analysis
InspireMD Risk Analysis
InspireMD Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $52.61M | 48.68 | -1.62% | ― | 3.30% | -112.70% | |
57 Neutral | $98.86M | ― | -77.26% | ― | -9.59% | 8.78% | |
51 Neutral | $7.77B | -0.12 | -39.78% | 2.21% | 22.68% | -1.42% | |
51 Neutral | $100.55M | ― | -123.51% | ― | 7.60% | -0.78% | |
46 Neutral | $67.78M | ― | -68.84% | ― | -7.81% | 65.39% | |
44 Neutral | $71.69M | ― | -177.75% | ― | ― | 4.91% | |
43 Neutral | $59.08M | ― | -230.80% | ― | -16.46% | 4.16% |
InspireMD Corporate Events
On August 5, 2025, InspireMD reported its financial results for the second quarter and the first half of 2025, highlighting significant milestones including FDA approval and the U.S. launch of its CGuard Prime carotid stent system. The company also secured $58 million through equity placement and warrant exercises, supporting its growth initiatives. Despite a slight increase in revenue, the company faced a net loss due to increased operating expenses related to sales force expansion and product launch preparations. InspireMD’s strategic moves are expected to position it as a leader in carotid artery disease treatment.
On July 30, 2025, InspireMD entered into a securities purchase agreement for a private placement offering, raising approximately $40.1 million through the sale of common stock and pre-funded warrants. The offering is expected to close by August 1, 2025, and includes a registration rights agreement to file a resale registration statement with the SEC. Additionally, InspireMD announced the full exercise of its Series I warrants, generating $17.9 million in gross proceeds, and the combined financings of $58 million will bolster the company’s balance sheet to commercialize its FDA-approved CGuard Prime carotid stent in the U.S. market. The company aims to use the proceeds for operations, including sales, marketing, and research and development, positioning itself as a leader in the carotid intervention market.
On July 9, 2025, InspireMD announced the U.S. commercial launch of its CGuard® Prime Carotid Stent System, following FDA premarket application approval. This launch represents a significant milestone for InspireMD, which has already captured a double-digit market share in over 30 countries. The CGuard Prime is designed to enhance embolic protection and improve patient safety in stroke prevention, featuring a dual-layer design and SmartFit™ technology. The launch is expected to strengthen InspireMD’s position in the U.S. market, supported by a seasoned commercial team and robust operational infrastructure.
On June 23, 2025, InspireMD announced that the FDA granted premarket approval for its CGuard Prime Carotid Stent System in the United States, marking a significant milestone for the company. The approval, supported by the C-GUARDIANS pivotal trial, positions InspireMD to launch the stent system in the U.S. market, potentially impacting the carotid stenting industry by offering a less invasive treatment option for carotid artery disease.
On June 13, 2025, InspireMD announced it received CE Mark approval under the European Medical Device Regulation (MDR) for its CGuard® Prime Embolic Prevention System (EPS), a significant milestone for the company. This approval allows for the commercial launch of CGuard® Prime EPS in European markets, enhancing InspireMD’s position in carotid stenting innovation and paving the way for a potential U.S. launch pending FDA approval, thereby expanding its market reach and operational scale.
On June 3, 2025, InspireMD, Inc. conducted its annual meeting of stockholders, where 66.84% of the shares were represented, constituting a quorum. During the meeting, stockholders re-elected Michael Berman and Scott R. Ward as Class 2 directors for a three-year term and ratified Kesselman & Kesselman as the independent auditors for the 2025 fiscal year.
On June 3, 2025, InspireMD announced the appointment of Michael Lawless as Chief Financial Officer, effective by June 30, 2025. Lawless, who brings extensive financial leadership experience from the healthcare sector, will replace Craig Shore, who has been with the company for nearly 15 years. This leadership change comes as InspireMD prepares for the U.S. launch of its CGuard Prime system, marking a significant phase in its commercial expansion. In connection with his appointment, Lawless will receive an inducement grant of restricted stock and stock options, which will vest over three years, aligning with Nasdaq Listing Rule 5635(c)(4).